Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 2, 2011, Pages 452-459

  Rezai, Pedram ^a   Yaghmai, Vahid ^a   Tochetto, Sandra M ^a   Galizia, Mauricio S ^a   Miller, Frank H ^a   Mulcahy, Mary F ^a   Small Jr , William ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Chemoradiotherapy; Doubling time; Growth rate; Pancreatic adenocarcinoma; Treatment response

Indexed keywords

ANTIGENS; CARBOHYDRATES; CHEMORADIOTHERAPY; HEALTH INSURANCE; PATIENT MONITORING; SURVEYS; TUMORS;

DOUBLING TIME; HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT COMPLIANT; INSTITUTIONAL REVIEW BOARDS; LINEAR REPRESENTATION; METHODS AND MATERIALS; PANCREATIC ADENOCARCINOMA; SEMI-AUTOMATED SEGMENTATION; TREATMENT RESPONSE;

GROWTH RATE;

BEVACIZUMAB; CA 19-9 ANTIGEN; GEMCITABINE;

ADULT; AGED; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RECIPROCAL OF DOUBLING TIME; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS GUIDELINE; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

EID: 80052796629     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.05.060     Document Type: Article

References (38)

1. T.L. Fitzgerald, Z.J. Hickner, and M. Schmitz Changing incidence of pancreatic neoplasms: A 16-year review of statewide tumor registry Pancreas 37 2008 134 138
2. C.M. Parsons, J.L. Sutcliffe, and R.J. Bold Preoperative evaluation of pancreatic adenocarcinoma J Hepatobiliary Pancreat Surg 15 2008 429 435
3. R. Marechal, A. Demols, and F. Gay Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic cancer Oncology 73 2007 41 51 (Pubitemid 351465599)
4. L. Vormittag, A. Gleiss, and W. Scheithauer Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer Oncology 77 2009 140 146
5. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
6. W. Small Jr., J. Berlin, and G.M. Freedman Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial J Clin Oncol 26 2008 942 947 (Pubitemid 351398088)
7. F. Kullmann, S. Hollerbach, and M.M. Dollinger Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: A multicentre phase II study Br J Cancer 100 2009 1032 1036
8. M.H. Kulke, L.S. Blaszkowsky, and D.P. Ryan Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer J Clin Oncol 25 2007 4787 4792 (Pubitemid 350086482)
9. Y.E. Kim, M.S. Park, and H.S. Hong Effects of neoadjuvant combined chemotherapy and radiation therapy on the CT evaluation of resectability and staging in patients with pancreatic head cancer Radiology 250 2009 758 765
10. J.Y. Lee, C.K. Kim, and D. Choi Volume doubling time and growth rate of renal cell carcinoma determined by helical CT: A single-institution experience Eur Radiol 18 2008 731 737
11. P. Rezai, M.F. Mulcahy, and S.M. Tochetto Morphological analysis of pancreatic adenocarcinoma on multidetector row computed tomography: Implications for treatment response evaluation Pancreas 38 2009 799 803
12. C.C. Jaffe Measures of response: RECIST, WHO, and new alternatives J Clin Oncol 24 2006 3245 3251 (Pubitemid 46622065)
13. C. Suzuki, H. Jacobsson, and T. Hatschek Radiologic measurements of tumor response to treatment: Practical approaches and limitations Radiographics 28 2008 329 344
14. C.D. Marcus, V. Ladam-Marcus, and C. Cucu Imaging techniques to evaluate the response to treatment in oncology: Current standards and perspectives Crit Rev Oncol Hematol 72 2009 217 238
15. R.L. Wahl, H. Jacene, and Y. Kasamon From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl. 1 2009 122S 150S
16. M. Kocherginsky, E.E. Cohen, and T. Karrison Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents J Biopharm Stat 19 2009 524 529
17. H.S. Wasan, G.M. Springett, and C. Chodkiewicz CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone Br J Cancer 101 2009 1162 1167
18. W.D. Stein, J. Yang, and S.E. Bates Bevacizumab reduces the growth rate constants of renal carcinomas: A novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage Oncologist 13 2008 1055 1062
19. S.Y. El Sharouni, H.B. Kal, and J.J. Battermann Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy Br J Cancer 89 2003 2184 2189 (Pubitemid 38167997)
20. R. Chojniak, and R.N. Younes Pulmonary metastases tumor doubling time: Assessment by computed tomography Am J Clin Oncol 26 2003 374 377 (Pubitemid 36962081)
21. S.M. Haney, P.M. Thompson, and T.F. Cloughesy Tracking tumor growth rates in patients with malignant gliomas: A test of two algorithms AJNR Am J Neuroradiol 22 2001 73 82 (Pubitemid 32105358)
22. E. Mehrara, E. Forssell-Aronsson, and H. Ahlman Specific growth rate versus doubling time for quantitative characterization of tumor growth rate Cancer Res 67 2007 3970 3975 (Pubitemid 46762187)
23. J. Zhang, S.K. Kang, and L. Wang Distribution of renal tumor growth rates determined by using serial volumetric CT measurements Radiology 250 2009 137 144
24. S.S. Graves, E. Dearstyne, and Y. Lin Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy Clin Cancer Res 9 2003 3712 3721 (Pubitemid 37169240)
25. A. Okamoto, K. Tsuruta, and N. Egawa Possibility of slow-growing variants in pancreatic adenocarcinoma Hepatogastroenterology 46 1999 522 526 (Pubitemid 29154810)
26. S.J. Gwyther, and L.H. Schwartz How to assess anti-tumour efficacy by imaging techniques Eur J Cancer 44 2008 39 45 (Pubitemid 350256945)
27. S.G. Jennings, H.T. Winer-Muram, and M. Tann Distribution of stage I lung cancer growth rates determined with serial volumetric CT measurements Radiology 241 2006 554 563 (Pubitemid 44632903)
28. H. Furukawa, R. Iwata, and N. Moriyama Growth rate of pancreatic adenocarcinoma: Initial clinical experience Pancreas 22 2001 366 369 (Pubitemid 32402085)
29. T. Hisa, H. Ohkubo, and S. Shiozawa Growth process of small pancreatic carcinoma: A case report with imaging observation for 22 months World J Gastroenterol 14 2008 1958 1960 (Pubitemid 351523834)
30. K. Nishida, T. Kaneko, and M. Yoneda Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis J Surg Oncol 71 1999 140 146 (Pubitemid 29340776)
31. K. Shimada, H. Onaya, and M. Esaki Slow growth of small pancreatic carcinoma with a 20-04 follow-up Pancreas 38 2009 346 349
32. Small W Jr., Mulcahy M, Benson A, et al. A phase II trial of weekly gemcitabine and bevacizumab in combination with abdominal radiation therapy in patients with localized pancreatic cancer. Presented at the Gastrointestinal Cancers Symposium-American Society of Clinical Oncology January 26th, 2008, Orlando, Fl.
33. J.M. Kuhnigk, V. Dicken, and L. Bornemann Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans IEEE Trans Med Imaging 25 2006 417 434
34. M. Schwartz A biomathematical approach to clinical tumor growth Cancer 14 1961 1272 1294
35. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
36. B.E. Van Beers, and V. Vilgrain Biomarkers in abdominal imaging Abdom Imaging 34 2009 663 667
37. R.S. Benjamin, H. Choi, and H.A. Macapinlac We should desist using RECIST, at least in GIST J Clin Oncol 25 2007 1760 1764 (Pubitemid 46797958)
38. G.M. Springett, and S.E. Hoffe Borderline resectable pancreatic cancer: On the edge of survival Cancer Control 15 2008 295 307